The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation. By integrating Céfiméca’s two production sites, the enlarged group reaches a critical mass of five manufacturing facilities and over 400 employees (combined), significantly enhancing its industrial capacity. The deal aims to improve market competitiveness by reducing lead times and offering a more integrated value chain, transitioning from a traditional supplier role to a strategic partnership model. The integration of Céfiméca’s high-value implant range specifically addresses the group's objective to master both the tools and the permanent devices used in joint and spinal procedures.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, a stable level compared to 2025. This data is based on the contribution of our growing community, composed of M&A and private equity professionals.